KTRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kintara Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.02 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.63 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kintara Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -585.21%. Kintara Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -585.21%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kintara Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -73.12%.
The historical data trend for Kintara Therapeutics's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
EBIT | Get a 7-Day Free Trial | -8.40 | -8.14 | -21.57 | -22.68 | -14.80 |
Kintara Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBIT | Get a 7-Day Free Trial | -3.50 | -3.30 | -3.35 | -2.96 | -1.02 |
For the Biotechnology subindustry, Kintara Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics (NAS:KTRA) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Kintara Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:
ROC % (Q: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2023 ) | + | Invested Capital (Q: Dec. 2023 )) | / count ) |
= | -4.076 * ( 1 - 0% ) | / | ( (0.694 | + | 0.699) | / 2 ) |
= | -4.076 | / | 0.6965 | |||
= | -585.21 % |
where
Invested Capital | (Q: Sep. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1.477 | - | 3.336 | - | ( 0.216 | - | max(0, 3.336 | - | 0.783 | + | 0.216 | )) |
= | 0.694 |
Invested Capital | (Q: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1.885 | - | 1.87 | - | ( 0.658 | - | max(0, 1.87 | - | 1.186 | + | 0.658 | )) |
= | 0.699 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.
2. Joel Greenblatt's definition of Return on Capital:
Kintara Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2023 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2023 | Q: Dec. 2023 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -4.076 | / | ( ( (0.694 + max(-2.769, 0)) | + | (0.699 + max(-1.653, 0)) ) | / | 2 ) |
= | -4.076 | / | ( ( 0.694 | + | 0.699 ) | / | 2 ) |
= | -4.076 | / | 0.6965 | ||||
= | -585.21 % |
where Working Capital is:
Working Capital | (Q: Sep. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0 | + | 0 | + | 0.567) | - | (3.336 | + | 0 | + | 0) |
= | -2.769 |
Working Capital | (Q: Dec. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (0.103 | + | 0 | + | 0.114) | - | (1.87 | + | 0 | + | 0) |
= | -1.653 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Kintara Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Dec. 2023 ) |
= | -10.632 | / | 14.540 | |
= | -73.12 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kintara Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Hoffman | director, officer: President and CEO | ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121 |
Anthony Scott Praill | officer: Chief Financial Officer | 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3 |
Saiid Zarrabian | director, officer: Head of Strategic Partnerships | P.O. BOX 675765, RANCHO SANTA FE CA 92067 |
Laura L. Johnson | director | C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122 |
Tamara A Seymour | director | C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
Toth Robert Joseph Jr | director | 543 LOMBARD ST, SAN FRANCISCO CA 94133 |
Dennis M Brown | officer: Chief Scientific Officer | 100 SAN MATEO DR, MENLO PARK CA 94025 |
Keith Murphy | director | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
John Liatos | director, officer: SVP, Business Development | 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
John K Bell | director | 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8 |
Napoleone Ferrara | director | 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101 |
Lynda Sarah Cranston | director | 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3 |
Erich Mohr | director | 8300 GREENSBORO DRIVE, MCLEAN VA 22102 |
Jeffrey Bacha | director | SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 11-28-2022
By PRNewswire PRNewswire • 04-14-2023
By PRNewswire PRNewswire • 11-30-2022
By PRNewswire • 12-07-2023
By PRNewswire • 10-11-2023
By PRNewswire • 06-28-2023
By PRNewswire • 10-31-2023
By PRNewswire PRNewswire • 10-19-2022
By PRNewswire • 10-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.